Effect of N-acetylcysteine supplementation in treatment of methadone maintenance treatment patients

The effect of N-acetylcysteine supplementation on psychological symptoms, oxidative stress, and inflammatory biomarkers in patients under methadone maintenance treatment

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170420033551N10

Enrollment

Registered

2020-09-19

Start date

2020-09-20

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Addiction. Other psychoactive substance related disorders

Interventions

Intervention 1: Intervention group: tablet of N-acetylcysteine, 600 mg (Ave sina, Tehran, Iran), four oral tablet for 12 weeks. Intervention 2: Control group: placebo tablet (Ave sina, Tehran, Iran),

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients under methadone maintenance treatment Age of 18 to 50 years old Evaluated by the drug abuse section of the Structured Clinical Interview for DSM-IV

Exclusion criteria

Exclusion criteria: Unwillingness to cooperate Consumption of antioxidant, and anti-inflammatory supplements during the last 3 months High blood pressure Hypothyroidism or hyperthyroidism Pregnant women

Design outcomes

Primary

Measure	Time frame
Depression. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Beck Depression Inventory (BDI).;Anxiety. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Beck Anxiety Inventory (BAI).;Sleep quality. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Pittsburgh Sleep Quality Index (PSQI).	—

Measure

Time frame

Depression. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Beck Depression Inventory (BDI).;Anxiety. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Beck Anxiety Inventory (BAI).;Sleep quality. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Pittsburgh Sleep Quality Index (PSQI).

—

Secondary

Measure	Time frame
Fasting plasma glucose. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Insulin. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Triglycerides. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;HDL. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Hs-CRP. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Total antioxidant. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.	—

Measure

Time frame

Fasting plasma glucose. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Insulin. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Triglycerides. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;HDL. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Hs-CRP. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Total antioxidant. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Ghaderi

Kashan University of Medical Sciences

gaderiam@yahoo.com+98 31 5554 0021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026